CD44s和CD44V6在非小细胞肺癌组织中的表达

目的 探讨CD44s和CD44V6在非小细胞肺癌（NSCLC）组织中的表达及与预后的关系。方法 应用免疫组织化学链霉素抗生物素蛋白过氧化物酶连接法（S－P法），对62例非癌组织和60例非小细胞肺癌组织进行了CD44s和CD44V6蛋白的检测。结果 CD44s和CD44V6在非癌组织中均有表达，前者的阳性表达率显著高于后者，P值小于0.05；CD44s在NSCLC的早期和无淋巴结转移时分别为72.7%和75％，显著高于中后期（50％）和有淋巴结转移者（50％），P值均小于0.05；CD44V6在NSCLC的中后期和有淋巴结转移时分别为84.2%和85％，显著高于早期（54.5%）和无淋巴结转移者（50％），P值均小于0.05。结论 CD44s强表达和CD44V6弱表达的NSCLC病人多为早期，发生转移的可能性较小，是NSCLC预后良好的一个指标，相反，预后较差。检测这两个指标可以指导NSCLC病人的临床治疗。

Expressions of CD44s and CD44V6 in non small cell lung carcinoma

Objective To study the expressions of CD44s and CD44V6 in non small cell lung carcinoma (NSCLC) and their significance in prognosis Methods 62 cases with benign disease and 60 cases with NSCLC were investigated to detect the expressions of CD44s and CD44V6 by immunohistochemistry (S P method) Results The positve expression rates of CD44s were much higher than those of CD44V6 in benign disease( P <0 005);The results also showed that CD44s in NSCLC were 72 7% and 75% respectively in early stage and without lymph node metastasis and were much higher than later stage and with lymph node metastasis (50% and 50% respectively),all P <0 005;CD44V6 positive expression rates in NSCLC in early stage and without lymph node metastasis(54 5% and 50% respectively )were significantly lower than those in later stage and with lymph node metastasis(84 2% and 85%),all P <0 05 Conclusion Most of the patients with CD44s high expressions and CD44V6 low expressions may be classified into early stage of NSCLC and have low rate of lymph node metastasis ,CD44s strong expression and CD44V6 low expression may be a better prognostic marker of NSCLC ,or the prognostic will be worse Through detecting the two markers may lead clinical treatment for NSCLC patients